453 A 26-Year Review of Long-term Safety of a Human Pasteurized C1 Inhibitor Concentrate
نویسندگان
چکیده
451 TheRelationship BetweenEmotional Cognition and the Symptom Gap inPatientswithBronchialAsthma: theEffects ofAlexithymia and Empathy Sonomi Nakajima. Clinical Psychology, Graduate School of Human Sciences, Osaka University, Suitashi, Japan. Background: When symptoms are poorly controlled, patients with bronchial asthma may show a symptom gap: a cognitive divergence between the true severity of symptoms and the severity evaluated by the patients themselves. The aim of this study was to determine which factors (emotional cognition of the self and others) are associated with this symptom gap. Methods: Forty-two patients with bronchial asthma, who were found with the Comprehensive Asthma Inventory (a bronchial asthma symptom questionnaire) to have psychosocial factors associated with a deep concern about the onset of asthma attacks, were studied by means of validated scales for alexithymia (the Toronto Alexithymia Scale-20) and for empathy (the Interpersonal Reactivity Index: IRI) and questions about how patients evaluate the severity of asthma. Results: Of the patients, 42.5% showed a cognitive divergence regarding asthma symptoms. The scores for “perspective taking” on the IRI were significantly higher in patients who felt symptoms were less severe than they actually than in patients who felt symptoms were more severe than they actually were. No association was found between alexithymia and the symptom gap. Conclusions: The results show that empathy, the ability to understand the emotions of others, is associated with a symptom gap in patients with bronchial asthma and that high scores for “perspective taking” on the IRI may indicate problems of treatment and symptom control in asthma.
منابع مشابه
A systematic review of the efficacy and safety of a purified, pasteurized C1 inhibitor concentrate for the treatment of patients with type I or II hereditary angioedema
Background Hereditary angioedema (HAE) is a rare disorder characterized by a congenital deficiency of the C1-inhibitor. It is a potentially fatal illness as laryngeal edema may lead to asphyxiation. Treatment of HAE is mainly performed with C1-inhibitor concentrate, icatibant, attenuated androgens, and antifibrinolytic agents. We conducted a systematic review to evaluate the efficacy and safety...
متن کاملPharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study
BACKGROUND Hereditary angioedema (HAE) is a rare disease caused by C1-esterase inhibitor (C1-INH) deficiency, characterized by periodic attacks of acute edema affecting subcutaneous (SC) tissues and mucous membranes. Human C1-INH concentrate given intravenously (IV) is effective and safe, but venous access may be difficult. We compared SC and IV administration of human pasteurized C1-INH concen...
متن کاملEfficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema
BACKGROUND The plasma-derived, pasteurized, nanofiltered C1-inhibitor concentrate (pnfC1-INH) is approved in the United States as an intravenous (IV) on-demand treatment for hereditary angioedema (HAE) attacks, and, in Europe, as on demand and short-term prophylaxis. OBJECTIVE This analysis evaluated Berinert Patient Registry data regarding IV pnfC1-INH used as long-term prophylaxis (LTP). ...
متن کاملTreatment of hereditary angioedema with plasma-derived C1 inhibitor
BACKGROUND Plasma-derived C1 inhibitor (C1-INH) concentrate is a treatment option for acute hereditary angioedema (HAE) attacks and is considered the standard-of-care in many countries, although it is not yet available in the United States. Studies are still being conducted to establish its safety and efficacy as required by the FDA. OBJECTIVE To review the medical literature to determine if ...
متن کاملLong Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P®
Factor XIII deficiency (FXIIID) is an extremely rare hemorrhagic disorder with a prevalence of 1/3-5 million. Management of disease is performed by fresh frozen plasma (FFP), Cryoprecipitate (CP) or FXIII concentrate (Fibrogammin P®). Our objective was to assess safety and effectiveness of Fibrogammin P® in patients with FXIIID. For this purpose we designed this long-term follow up study on a l...
متن کامل